Director
Ali Behbahani, M.D., M.B.A.
Ali Behbahani, M.D., M.B.A., has served on our Board of Directors since April 2015. He is a Partner and Co-Head of the Healthcare team at New Enterprise Associates, Inc. (NEA), where he has worked since 2007.
Dr. Behbahani brings extensive board experience across the biopharmaceutical and biotechnology sectors. He currently serves on the boards of Adaptimmune Therapeutics plc (ADAP) since 2014; Nkarta, Inc. (NKTX) since 2015, and Chairman since 2019; Black Diamond Therapeutics, Inc. (BDTX) since 2018; Monte Rosa Therapeutics, Inc. (GLUE) since 2020; Korro Bio, Inc. (KRRO) since 2019; and Arcellx, Inc. (ACLX) since 2015. His past board roles include CVRx, Inc. (CRVX), Minerva Surgical Inc. (UTRS), Oyster Point Pharma, Inc., and Genocea Biosciences, Inc.
Before joining NEA, he held roles in healthcare investment banking and corporate development, including positions at Lehman Brothers, Morgan Stanley, and The Medicines Company.
Dr. Behbahani earned his M.D. from the University of Pennsylvania School of Medicine and an M.B.A. with honors from the Wharton School, where he was named a Palmer Scholar. He also holds a B.S. in Biomedical Engineering, Electrical Engineering, and Chemistry from Duke University.
